Close Menu

This story has been updated with additional comments from Elaine Mardis during the plenary clinical trials session of the AACR annual meeting. The headline has also been updated.

NEW YORK − BioNTech's personalized cancer vaccine RO7198457 combined with the PD-L1 inhibitor atezolizumab (Genentech's Tecentriq) appears to be active and well tolerated in patients with solid tumors, according to new data presented at the second virtual session of the American Association for Cancer Research's annual meeting last Friday.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.